In parallel with the other attempts to extend the use of EGFR-TKIs in the early-stage setting, the EGFR-TKI strategy has started to be explored in unresectable stage III EGFR-mutant NSCLC as well (Table 2). Here, EGFR is linked to non-small cell lung carcinoma.